TMX Newsfile·2026-02-15 03:26Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for allegedly providing misleading information regarding the efficacy of its drug setrusumab during clinical trials, leading to inflated stock prices for investors who purchased shares between August 3, 2023, and December 26, 2025 [1][5][6]. Group 1: Lawsuit Details - The lawsuit claims that Ultragenyx's management made overly positive statements about setrusumab's ability to reduce fracture rates in Osteogenesis Imperfecta patients while concealing material adverse facts about the drug's actual efficacy [5][6]. - It is alleged that the Phase III Orbit and Cosmic studies were less likely to demonstrate the claimed benefits than management suggested, which misled investors [6]. Group 2: Investor Information - Investors who purchased Ultragenyx common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][7]. Group 3: Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].